Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL7459255 | 0.82 | HTR1A (0.57) | HTR1AADRA1A | |
| SCHEMBL19984361 | 0.81 | HTR1A (0.50) | HTR1AADRA1A | |
| SCHEMBL19971721 | 0.81 | HTR1A (0.58) | HTR1AADRA1A | |
| SCHEMBL7466895 | 0.80 | HTR1A (0.57) | HTR1AADRA1A | |
| SCHEMBL6983237 | 0.80 | HTR1A (0.63) | HTR1AADRA1A | |
| SCHEMBL6981877 | 0.79 | HTR1A (0.62) | HTR1AADRA1A | |
| SCHEMBL6985467 | 0.78 | HTR1A (0.55) | HTR1AADRA1A | |
| SCHEMBL2653348 | 0.78 | HPGD (0.73) | HTR1A | |
| SCHEMBL2075037 | 0.78 | HPGD (0.68) | HTR1A | |
| SCHEMBL19984149 | 0.78 | HTR1A (0.60) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290992-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10626105-B2 | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds | AUSPEX PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290992-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | HTR1A 3/4885ADRA1A 82/4885 |
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | HTR1A 3/4885ADRA1A 82/4885 |
| US-10626105-B2 | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds | HTR2C, HTR5A, HTR1A | HTR1A 3/4885ADRA1A 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.